Home » Clinical Trials » Therapeutic Areas

Therapeutic Areas: Nephrology | Urology | Family Medicine
Disease Category: Erectile Dysfunction
Location: United States, FL

Clinical Trial Details

Overview

Research Study Summary

An Open-Label Trial Of Oral Selegiline 5 Or 10 Mg And Tadalafil 2.5 Mg Co-Administration To Male Patients With Parkinson's Disease And Moderate Erectile Dysfunction.

Purpose

The purpose of this study is to see if selegiline and tadalafil (generic for Cialis®) results in an improvement in Erectile dysfunction (ED) in male patients with Parkinson's disease (PD) and moderate ED. Male PD patients who have an incomplete response to tadalafil alone will be given both medications to see if the addition of selegiline improves ED symptoms more than tadalafil alone. It is common practice for a medical doctor to prescribe these two drugs to a patient like you. However, there have been no studies conducted to examine the effects of these medications when taken together.

Selegiline is normally prescribed for PD patients that are taking carbidopa/levodopa who are not receiving complete benefit from carbidopa/levodopa.

Tadalafil is normally prescribed to men who have erectile dysfunction and/or benign prostatic hyperplasia (BPH).

To Learn more

CW ID: 201181
Date Last Changed: May 27, 2015

Clinical Trial Snapshot

Phase
4
Gender
Male
Age
40 to 64 Years
Overall Status
Recruiting
Lead Sponsor
Sagene Pharmaceuticals
Facility Type
N/A

Contact

Kevin Allison
University of South Florida - Morsani Center for Advance Healthcare
13330 USF Laurel Drive
Tampa, FL 33612
Phone: (813)974-9915

View Map

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.